Clinical relevance of human leukocyte antigen antibodies in kidney transplantation from deceased donors: The North Italy Transplant program approach

Human Immunology

Volumn 70, Issue 8, 2009, Pages 631-635

  Poli, Francesca ^a   Cardillo, Massimo ^a   Scalamogna, Mario ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIBODY; HLA ANTIGEN CLASS 2; IMMUNOGLOBULIN;

ANALYTICAL EQUIPMENT; ANTIBODY DETECTION; ANTIBODY SCREENING; ARTICLE; CADAVER KIDNEY; CLINICAL PROTOCOL; COMPLEMENT DEPENDENT CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GRAFT SURVIVAL; HEALTH CARE POLICY; HLA MATCHING; HOSPITAL ADMISSION; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; ITALY; KIDNEY GRAFT REJECTION; KIDNEY INJURY; KIDNEY TRANSPLANTATION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURGICAL APPROACH;

CADAVER; COMPLEMENT SYSTEM PROTEINS; CYTOTOXICITY, IMMUNOLOGIC; DESENSITIZATION, IMMUNOLOGIC; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNOSORBENT TECHNIQUES; ISOANTIBODIES; ITALY; KIDNEY TRANSPLANTATION; MICROSPHERES; MONITORING, PHYSIOLOGIC; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; PROGRAM EVALUATION; RETROSPECTIVE STUDIES; RISK FACTORS; TISSUE AND ORGAN PROCUREMENT; TISSUE DONORS; TRANSPLANTATION CONDITIONING; WAITING LISTS;

EID: 68249109181     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2009.06.006     Document Type: Article

References (42)

1. Gabel H. Comments on the Spanish model. II. In: Matesanz R., and Miranda B. (Eds). Organ donation for transplantation (1996), Madrid
2. De Meester J., Doxiadis I.I., Persijn G.G., and Claas F.H. Renal transplantation of highly sensitised patients via prioritised renal allocation programs. Shorter waiting time and above-average graft survival. Nephron 92 (2002) 111-115
3. Lee P.C., and Ozawa M. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation. In: Terasaki P. (Ed). Clin Transpl 2007 (2008), Terasaki Foundation Laboratory, Los Angeles, CA 219-226
4. Fuggle S.V., and Martin S. Tools for human leukocyte antigen antibody detection and their application to transplanting sensitized patients. Transplantation 86 (2008) 384-390
5. Susal C., and Opelz G. Options for immunologic support of renal transplantation through the HLA and immunology laboratories. Am J Transpl 7 (2007) 1450-1456
6. Bray R.A., Nolen J.D., Larsen C., Pearson T., Newell K.A., Kokko K., et al. Transplanting the highly sensitized patient: the emory algorithm. Am J Transplant 6 (2006) 2307-2315
7. Eckels D.D. Solid phase testing in the HLA laboratory: implications for organ allocation. Int J Immunogenet 35 (2008) 265-274
8. Slavcev A., Lácha J., Honsová E., et al. Clinical relevance of antibodies to HLA antigens undetectable by the standard complement-dependent cytotoxicity test. Transpl Int 16 (2003) 872-878
9. Jordan S.C., Vo A., Tyan D., and Toyota M. Desensitization therapy with intravenous gammaglobulin (IVIG): applications in solid organ transplantation. Trans Am Clin Climatol Assoc 117 (2006) 199-211
10. Tyan D.B., Li V., Czer L., Trento A., and Jordan S.C. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation 57 (1994) 553-562
11. Cardillo M., Poli F., Barraco F., et al. Renal transplantation. Strategies to prevent organ rejection-the role of an inter-regional reference center. Contrib Nephrol 146 (2005) 1-10
12. Sirchia G., Poli F., Cardillo M., Scalamogna M., Rebulla P., Taioli E., et al. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation. In: Terasaki P. (Ed). Clin Transpl 1998 (1999), Terasaki Foundation Laboratory, Los Angeles, CA 133-145
13. Cardillo M., Scalamogna M., Pizzi C., et al. Kidney transplantation in the north Italy transplant program. Clin Transpl (2000) 371-373
14. Zachary A.A., Montgomery R.A., and Leffell M.S. Defining unacceptable HLA antigens. Curr Opin Organ Transplant 13 (2008) 405-410
15. Doxiadis I.I., Duquesnoy R.J., and Claas F.H. Extending options for highly sensitized patients to receive a suitable kidney graft. Curr Opin Immunol 17 (2005) 536-540
16. Colombo M.B., Haworth S.E., Poli F., et al. Luminex technology for anti-HLA antibody screening: evaluation of performance and of impact on laboratory routine. Cytometry B Clin Cytom 72 (2007) 465-471
17. Poli F., Haworth S., Nocco A., Gotti E., Boschiero L., Dissegna E., et al. Antibody cases. In: Terasaki P. (Ed). Clin Transpl 2006 (2007), Terasaki Foundation Laboratory, Los Angeles, CA 483-488
18. Claas F.H. HLA antibody testing: a tool to facilitate not to prevent organ transplantation. Int J Immunogenet 35 (2008) 275-277
19. Montgomery R.A., Zachary A.A., Racusen L.C., et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 70 (2000) 887-895
20. Vieira C.A., Agarwal A., Book B.K., et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. Transplantation 77 (2004) 542-548
21. Sirchia G., Mercuriali F., Scalamogna M., et al. Preexistent anti-HLA-DR antibodies and kidney graft survival. Transplant Proc 11 (1979) 950-953
22. Ettinger R.B., Terasaki P.I., Opelz G., et al. Successful renal allografts across a positive cross-match for donor B-lymphocyte alloantigens. Lancet 2 (1976) 56-58
23. Ting A., and Morris P.J. Renal transplantation and B-cell cross-matches with autoantibodies and alloantibodies. Lancet 2 (1977) 1095-1097
24. Ayoub G., Park M.S., Terasaki P.I., Iwaki Y., and Opelz G. B cell antibodies and crossmatching. Transplantation 29 (1980) 227-229
25. Süsal C., and Opelz G. Good kidney transplant outcome in recipients with presensitization against HLA class II but not HLA class I. Hum Immunol 65 (2004) 810-816
26. Pollinger H.S., Stegall M.D., Gloor J.M., et al. Kidney transplantation in patients with antibodies against donor HLA class II. Am J Transplant 7 (2007) 857-863
27. Slavcev A., Lacha J., Sajdlova H., et al. Antibodies to HLA class II antigens as a risk factor for acute rejection of the allogeneic kindey. Ann Transplant 9 (2004) 44-47
28. Delgado J.C., and Eckels D.D. Positive B-cell only flow cytometric crossmatch: implications for renal transplantation. Exp Mol Pathol 85 (2008) 59-63
29. Ho E.K., Vasilescu E.R., Colovai A.I., et al. Sensitivity, specificity and clinical relevance of different cross-matching assays in deceased-donor renal transplantation. Transpl Immunol 20 (2008) 61-67
30. Vasilescu E.R., Ho E.K., Colovai A.I., et al. Alloantibodies and the outcome of cadaver kidney allografts. Hum Immunol 67 (2006) 597-604
31. Süsal C., Pelzl S., Simon T., and Opelz G. Advances in pre- and posttransplant immunologic testing in kidney transplantation. Transplant Proc 36 (2004) 29-34
32. Patel R., and Terasaki P.I. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 280 (1969) 735-739
33. Chapman J.R., Taylor C.J., Ting A., and Morris P.J. Immunoglobulin class and specificity of antibodies causing positive T cell crossmatches. Relationship to renal transplant outcome. Transplantation 42 (1986) 608-613
34. McCalmon Jr. R.T., Tardif G.N., Sheehan M.A., Fitting K., Kortz W., and Kam I. IgM antibodies in renal transplantation. Clin Transplant 11 (1997) 558-564
35. Tardif G.N., and McCalmon Jr. R.T. Successful renal transplantation in the presence of donor specific HLA IgM antibodies. Transplant Proc 27 (1995) 664-665
36. Roelen D.L., van Bree J., Witvliet M.D., et al. IgG antibodies against an HLA antigen are associated with activated cytotoxic T cells against this antigen, IgM are not. Transplantation 57 (1994) 1388-1392
37. Gebel H.M., Bray R.A., and Nickerson P. Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: contraindication vs. risk. Am J Transplant 3 (2003) 1488-1500
38. Bingaman A.W., Murphey C.L., Palma-Vargas J., and Wright F. A virtual crossmatch protocol significantly increases access of highly sensitized patients to deceased donor kidney transplantation. Transplantation 86 (2008) 1864-1868
39. Vaidya S. Clinical importance of anti-human leukocyte antigen-specific antibody concentration in performing calculated panel reactive antibody and virtual crossmatches. Transplantation 85 (2008) 1046-1050
40. Zangwill S., Ellis T., Stendahl G., Zahn A., Berger S., and Tweddell J. Practical application of the virtual crossmatch. Pediatr Transplant 11 (2007) 650-654
41. Tambur A.R., Leventhal J., Kaufman D.B., Friedewald J., Miller J., and Abecassis M.M. Tailoring antibody testing and how to use it in the calculated panel reactive antibody era: the Northwestern University experience. Transplantation 86 (2008) 1052-1059
42. Piazza A., Poggi E., Ozzella G., et al. Public epitope specificity of HLA class I antibodies induced by a failed kidney transplant: alloantibody characterization by flow cytometric techniques. Transplantation 81 (2006) 1298-1305